Search company, investor...

Predict your next investment

Global Brain company logo
Venture Capital
FINANCE | Investment Firms & Funds
globalbrains.com

Investments

294

Portfolio Exits

28

Funds

8

Partners & Customers

4

About Global Brain

Global Brain is a Tokyo-based venture capital firm that specializes in investing in and supporting startups that are looking to expand their business overseas.

Headquarters Location

10-11 Sakuragaokacho Shibuya-ku

Tokyo, 150-0031,

Japan

Want to inform investors similar to Global Brain about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Global Brain News

Startups measuring the brain that you need to know

Jan 23, 2023

Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization  found the global prevalence of anxiety and depression increased by 25% in the first year of the COVID-19 pandemic. But perhaps the rates of depression are also grossly exaggerated: consider that the number of people diagnosed with depression is inflated. Studies as far back as 2013, such as one from Johns Hopkins Bloomberg School of Public Health, showed that 60% of people diagnosed with depression didn't meet the clinical criteria for such a condition. This has led to increased demand for better diagnostic tools. As it stands right now, the best way to diagnose issues like depression and anxiety is self-reported data from questionnaires like the PHQ-9 and the GAD-7, but what if you could actually measure the brain itself for signs of these diseases through specific biomarkers? And what if you could also alter the brain using those same biomarkers to treat them? That's what is starting to happen now; companies like Ellipsis Health are studying biomarkers to assess of the severity of anxiety and depression, while others like, Alto Neuroscience, are studying the brain to match the right patient with the right, and others, like Fisher Wallace, are creating wearables that treats the brain electrically to relieve depression, anxiety and insomnia. Here are some companies pioneering this space for mental health, as well as other neurological conditions and disorders like Alzheimer’s disease and amblyopia: Description: "Through our proprietary precision data science platform, we aim to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics and increase the probability of developing effective medicines. Our platform integrates multiple types of data to create Data Biopsy Signatures and Precision Phenotypes to map disease drivers to the defined patient subtypes" Founded: 2019 Last funding round: $112 million in October 2022 Investors: Polaris Partners, ARCH Venture Partners, SoftBank Vision Fund, F-Prime Capital, Alexandria Venture Investments, Invus, Surveyor Capital, Mubadala Capital Ventures, Logos Capital, Catalio Capital Management, Altitude Life Science Ventures, EXOR N.V., re.Mind Capital, Amgen, Newpath Management, Abu Dhabi Growth Fund, Waycross Ventures Founded: 2017 Last funding round:  $46 million in November 2022 Investors: The Column Group, Eventide Management Partners, Third Rock Ventures, Amgen Ventures, The Column Group, Mirae Asset, Astellas Venture Management, Michael J. Fox Foundation, Eventide, Euclidean Capital, Schroder Adveq, Eisai, Schroders Capital, Ono Venture Investment, Eventide Management Partners Description: "Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies" Founded: 2014 Last funding round:  $77 million in November 2021 Investors: Ascension Ventures, PEAK6 Investments, GV, Lux Capital, StartUp Health, Novartis Venture Fund, Baird Capital, Johnson & Johnson Development Corporation, Dolby Family Ventures, Ascension Ventures, Johnson & Johnson Innovation, Lightstone Ventures, Triventures, LifeSci Venture Partners, dRx Capital, Action Potential Venture Capital, Innovatus Capital Partners Description: "Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders. We are developing these disease modifying treatments by leveraging our expertise in inhibiting protein misfolding and aggregation" Founded: 2013  Investors: National Institute on Aging, Ally Bridge Group, Scott H. Cohen Description: "MicroTransponder Inc. has developed the Paired Vagus Nerve Stimulation Platform (Paired VNS™ Platform), based on decades of neuroscience research. The Vivistim System, for treatment of post-stroke upper limb mobility issues, is the first FDA-approved system on the platform. MicroTransponder is researching ways to expand the Paired VNS platform to help patients with other chronic neurologic conditions" Founded: 2007 Last funding round: $53 million in June 2022 Investors: Action Potential Venture Capital, U.S. Venture Partners, Osage University Partners, Green Park & Golf Ventures, The Vertical Group, UT Horizon Fund, Action Potential Venture Capital, GPG Ventures Investors: Undisclosed Description: "We are developing a cloud-based platform to map brain network activity using explanatory machine learning algorithms to extract biological insights that translate into precision therapies. The therapies are delivered via an investigational non-invasive portable medical device that creates a frequency-tuned low-intensity electromagnetic field" Founded: 2016 Last funding round: $40 million in August 2021 Investors: Amir Gross, Qure Ventures, Norma Investment, Dexcel Pharma, Sailing Capital, Millhouse, Hanaco Venture Capital, Peregrine Ventures, IT-Farm, OurCrowd Description: "Harnessing the human voice as a biomarker for mental health and wellbeing along with machine learning and AI, Ellipsis Health generates a clinical-grade assessment of the severity of anxiety and depression, as well as a sub-clinical assessment of the severity of stress" Founded: 2017 Last funding round: $26 million in June 2021 Investors: Alumni Ventures, Khosla Ventures, Greycroft, Gaingels,10X Capital, City Light Capital, SJF Ventures Able Partners, What If Ventures, Time Ventures, SpringTide Ventures, Luminous Ventures Generator Ventures, Richard Socher, Gyan Kapur, Akhil Paul, Ricardo Marino, Joanne Bradford, Gary Loveman, Divesh Makan, Helmy Eltoukhy Description: "Kintsugi is the art of repairing fractures in ceramics with gold. What once was broken becomes stronger and more beautiful. We bring this philosophy to strengthening mental wellness infrustructures. So instead of falling through the cracks, more people can embrace their flaws and find beauty in their growth" Founded: 2019  Last funding round: $20 million in February 2022 Investors: Primetime Partners, AngelList Talent, National Science Foundation, Techstars, MassChallenge, Insight Partners, Alpha Edison, Acrew Capital, IT-Farm, On Deck, Darling Ventures, Primetime Partners, Side Door Ventures, Eric Yuan, Citta Capital, KidsX, Adam Grosser Description: "NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company is commercializing the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch and NeuroSigma's TNS platform include a wide spectrum of neurological and neuropsychiatric disorders, such as ADHD, drug-resistant epilepsy, and depression." Founded: 2008 Founded: 2016 Last funding round: $9 million in August 2021 Investors: Schox Patent Group, Zühlke Ventures AG, SOSV, Khosla Ventures, HAX, Global Brain Corporation, Redstone, Kirin Holdings, Schox Patent Group, SwissHealth Ventures, Daniel Andersson Description: "Blackrock Neurotech provides innovative tools and neurotech expertise to translate technology into novel, implantable clinical solutions that improve human lives. Blackrock’s precision electrode technology is at the core of many worldwide Brain-Computer Interface (BCI) innovations. Our technology has enabled BCI Pioneers to walk, talk, see, hear, and feel again." Founded: 2008 Last funding round: $10 million in May 2021 Investors: What If Ventures, Presight Capital, Peter Thiel, re.Mind Capital, WPSS.bio, Kliwla Family Office AG,  Sorenson Impact, Tim Sievers Founded: 2015 Last funding round: $6 million in December 2019 Investors: National Science Foundation, FundersClub, PJC, M Ventures, Erik Peterson, NXT Ventures, TRAC, Boston Syndicates, Innospark Ventures, Cold Start Ventures, Loup Ventures, Hartmann Capital, Fady Hannah-Shmouni, Zell Lurie Commercialization Fund, Robert Winter Description: "Our patented technology treats the brain electrically to relieve depression, anxiety and insomnia. It works by stimulating the brain to release serotonin and other neurotransmitters required for healthy mood and sleep, while also lowering cortisol and modulating the center brain regions responsible for managing the sympathetic nervous system (known as the "fight or flight" response). Most patients report symptom reduction within the first 1-2 weeks of use" Founded: 2007

Global Brain Investments

294 Investments

Global Brain has made 294 investments. Their latest investment was in Visolis as part of their Seed VC on January 1, 2023.

CBI Logo

Global Brain Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/11/2023

Seed VC

Visolis

$8M

Yes

5

12/20/2022

Series A - II

Rest Less

$7.22M

Yes

1

12/20/2022

Seed VC

Bakool

Yes

2

12/20/2022

Seed VC

Subscribe to see more

Subscribe to see more

10

12/16/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/11/2023

12/20/2022

12/20/2022

12/20/2022

12/16/2022

Round

Seed VC

Series A - II

Seed VC

Seed VC

Series B

Company

Visolis

Rest Less

Bakool

Subscribe to see more

Subscribe to see more

Amount

$8M

$7.22M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

1

2

10

10

Global Brain Portfolio Exits

28 Portfolio Exits

Global Brain has 28 portfolio exits. Their latest portfolio exit was Foodison on December 16, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/16/2022

IPO

$99M

Public

2

11/15/2022

IPO

$99M

Public

2

5/19/2022

Acq - Pending

$99M

1

4/27/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/1/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/16/2022

11/15/2022

5/19/2022

4/27/2022

3/1/2022

Exit

IPO

IPO

Acq - Pending

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

Global Brain Fund History

8 Fund Histories

Global Brain has 8 funds, including 321FORCETM Global Innovation Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/5/2022

321FORCETM Global Innovation Fund

$36.83M

2

2/8/2022

TOKYU-CONST GB Innovation Fund

$99M

10

7/7/2017

GB-VI Growth Fund Investment Limited Partnership

$99M

10

11/22/2013

GB-V Growth Fund Investment Limited Partnership

10

Global Brain Fund VIII

10

Closing Date

7/5/2022

2/8/2022

7/7/2017

11/22/2013

Fund

321FORCETM Global Innovation Fund

TOKYU-CONST GB Innovation Fund

GB-VI Growth Fund Investment Limited Partnership

GB-V Growth Fund Investment Limited Partnership

Global Brain Fund VIII

Fund Type

Status

Amount

$36.83M

$99M

$99M

Sources

2

10

10

10

10

Global Brain Partners & Customers

4 Partners and customers

Global Brain has 4 strategic partners and customers. Global Brain recently partnered with Kirin Holdings Company on September 9, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

9/23/2020

Partner

Japan

Global Brain partners with KIRIN Holdings on its corporate venture capital fund

Global Brain Corporation and Kirin Holdings Company , Limited have partnered to launch the KIRIN HEALTH INNOVATION FUND , a corporate venture capital having JPY 5 Billion of committed capital .

1

4/1/2020

Partner

Japan

Subscribe to see more

Subscribe to see more

10

3/28/2018

Partner

Japan

Subscribe to see more

Subscribe to see more

10

12/7/2017

Partner

Singapore

Subscribe to see more

Subscribe to see more

10

Date

9/23/2020

4/1/2020

3/28/2018

12/7/2017

Type

Partner

Partner

Partner

Partner

Business Partner

Country

Japan

Japan

Japan

Singapore

News Snippet

Global Brain partners with KIRIN Holdings on its corporate venture capital fund

Global Brain Corporation and Kirin Holdings Company , Limited have partnered to launch the KIRIN HEALTH INNOVATION FUND , a corporate venture capital having JPY 5 Billion of committed capital .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Global Brain Team

1 Team Member

Global Brain has 1 team member, including current Founder, Chief Executive Officer, Owner, Yasuhiko Yurimoto.

Name

Work History

Title

Status

Yasuhiko Yurimoto

Founder, Chief Executive Officer, Owner

Current

Name

Yasuhiko Yurimoto

Work History

Title

Founder, Chief Executive Officer, Owner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.